Pharmacology of 3,5-diamino-1,24-triazole (guanazole). 1. Antitumor activity of guanazole.
D000588:Amines / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002279:Carcinoma 256, Walker / Q000517:prevention & control; D003520:Cyclophosphamide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D003864:Depression, Chemical; D005260:Female; D006918:Hydroxyurea / Q000494:pharmacology; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000517:prevention & control*; D007942:Leukemia, Experimental / Q000401:mortality / Q000517:prevention & control*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000517:prevention & control; D008297:Male; D012515:Mast-Cell Sarcoma / Q000517:prevention & control; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D009374:Neoplasms, Experimental / Q000401:mortality; D009607:Nitrosourea Compounds / Q000494:pharmacology; D010954:Plasmacytoma / Q000517:prevention & control; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology*
D000588:Amines; D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D014230:Triazoles; D003561:Cytarabine; D003520:Cyclophosphamide; D006918:Hydroxyurea; D008727:Methotrexate